OSSIO introduces OSSIOfiber® Threaded Trimmable Fixation Nail to improve orthopedic surgery and simplify inventory management
Use cases for latest addition to company’s expanding product portfolio include hand and wrist, foot and ankle, sports medicine, and pediatric applications
“Same compression. Zero metal. Nothing left behind.”
WOBURN, Mass., November 14, 2024 –(BUSINESS WIRE)–OSSIO, Inc., a fast-growing medical technology company focused on evolving orthopedic surgery with bio-integrative fixation implants, recently expanded its product portfolio by introducing the OSSIOfiber® Threaded Trimmable Fixation Nail.
The latest addition to the company’s line of OSSIOfiber implants apply to an array of orthopedic surgeries:
- hand and wrist
- foot and ankle
- sports medicine
- pediatrics
William Crawford, M.D, an orthopedic surgeon at Texas Orthopedic Associates in Fort Worth, was among the first to use the OSSIOfiber Threaded Trimmable Fixation Nail, in an interphalangeal joint fusion of the great toe. He also used the new implant in a Lisfranc repair, first metatarsophalangeal (MTP) joint fusion, and a calcaneal osteotomy.
“The instrumentation that comes with each implant makes customization simple and easy, because it enables the surgeon to trim the implant’s length, right there in the O.R., to accommodate each patient’s unique fixation requirements,” explained Dr. Crawford, who also serves as a team physician for Texas Christian University athletics. “The simplicity of offering one length that can be trimmed to size—and everything you need in one single-use, sterile pack—is a game changer for inventory management in surgical centers where storage space is limited, cutting down on both cost and complexity.”
About OSSIOfiber® Threaded Trimmable Fixation Nails
OSSIOfiber Threaded Trimmable Fixation Nails accommodate two distinct applications: One system covers fixation of fractures in the extremities; the other system specifically covers hand and wrist fractures.
Two leading orthopedic surgeons contributed to the differentiated design of the latter system, specifically for metacarpal fracture fixation:
- Meredith Osterman, M.D, an orthopedic surgeon with Philadelphia Hand to Shoulder Center
- Jerry Huang, M.D., a professor of orthopedic surgery and sports medicine and chief of the orthopedic hand service at the University of Washington
“Metacarpal fractures are common in younger, active patients, often from sports or falls,” Dr. Huang said. “Having a solution that integrates into the fractured bone over time—without the risks of long-term hardware retention—is a significant advancement in metacarpal fixation and key to restoring these patients’ mobility quickly. For surgeons, OSSIOfiber implants put to rest the potential nightmare of broken or stuck metal screws, which can be very challenging to remove.”
Dr. Osterman added: “For patients, the thought of permanent metal in their hands is often unsettling. OSSIOfiber implants feature a unique material that mirrors bone properties, offering a solution that’s effective in both fixation and long-term integration into the body’s own anatomy. They also leverage a technique every orthopedic surgeon already knows.”
OSSIOfiber Threaded Trimmable Fixation Nails are 70mm long and come in two diameters: 4.5mm and 5.5mm. They also come with a sterilized and disposable instrument pack.
INDICATIONS FOR USE
OSSIOfiber Threaded Trimmable Fixation Nails are indicated for maintenance of alignment and fixation of bone fractures, comminuted fractures, fragments, osteotomies, arthrodesis, and bone grafts, of the upper extremity, fibula, knee, ankle and foot in the presence of appropriate brace and/or immobilization in adults and children (2–12 years) and adolescents (12–21 years) in which growth plates have fused or in which growth plates will not be crossed by fixation.
About OSSIOfiber® implants
Notably for U.S. healthcare providers and payors, OSSIOfiber implants utilize existing reimbursement codes and surgical techniques. Their uptake continues to grow because of strong patient and surgeon preference to avoid the concerns and complications of metal fixation implants. Looking ahead, OSSIO intends to continue developing additional applications for OSSIOfiber implants in all major segments of orthopedics.
“OSSIOfiber bio-integrative implants have been used in more than 40,000 orthopedic surgeries since our first launch in 2019,” according to OSSIO CEO Brian Verrier. “Over the last five years, we’ve brought 10 new product platforms to U.S. orthopedic surgeons, making OSSIOfiber implants applicable in dozens of surgical scenarios across upper and lower extremities, trauma, sports medicine, and pediatrics. We will continue to invest in our new product pipeline, which is driven by where we can add the greatest value to the patient and surgeon experience.”
All OSSIOfiber implants feature a revolutionary advance in material science stronger than cortical bone, providing the first credible alternative to metal, absorbable and allograft fixation devices. With the potential to address an increasingly wide array of surgical applications due to the ease of manufacturing limitless variations, they are engineered to provide the strength required for functional fixation while allowing for full integration into patients’ native anatomy without adverse biological response.
Based on Intelligent Bone Regeneration Technology, OSSIOfiber implants combine unparalleled mechanical strength and natural healing in a bio-integrative design. Their proprietary polymeric mineral fiber matrix propels rapid bone in-growth, regeneration and replacement—a new way for orthopedic surgeons to restore stability and mobility for their patients’ fractures while leaving nothing permanent behind.
About OSSIO
OSSIO is an orthopedic fixation company committed to transforming the surgical experience for patients, physicians, providers, and payors. Founded in 2014, the company’s vision is to provide the first credible replacement for metal implants in the multibillion-dollar global orthopedic fixation market with OSSIOfiber Intelligent Bone Regeneration Technology.
For more information on OSSIOfiber implants and OSSIO, which has development headquarters in Caesarea, Israel, and commercial headquarters in Woburn, Mass., visit www.ossio.io.
DISCLAIMER
Forward-looking statements contained herein are based on estimates and assumptions of OSSIO management and are believed to be reasonable, though they are inherently uncertain and difficult to predict.
Contacts
Joe McGrath
Scope Strategic Communications
contactmcgrath@gmail.com
+1-612-819-6421
